The company will start a phase 2/3 trial of its Mirati-originated PRMT5 inhibitor in autumn.
ApexOnco Front Page
Recent articles
LaNova, which licensed a PD-1 x VEGF to Merck, is acquired by another Chinese player.
But ficerafusp is limited to HPV-negative disease, and petosemtamab’s safety looks better.
Predictably Tacti-003 fails, but funding is secured – from investors, not a partner.
A complete response letter for Merck & Co and Daiichi’s patritumab deruxtecan might not be fatal, but it’s certainly embarrassing.
The group plays down upcoming interim analysis, but still hopes for accelerated approval.
The ROR1 data are sketchy, and lung toxicity clouds prospects.
A second Lilly Nectin-4 ADC features among the latest phase 1 initiations.